Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.

被引：0

作者：

Castagnola, C ^{[1
]}

Alessandrino, EP ^{[1
]}

Pagnucco, G ^{[1
]}

Bernasconi, P ^{[1
]}

Lunghi, M ^{[1
]}

Colombo, A ^{[1
]}

Brusamolino, E ^{[1
]}

Bonfichi, M ^{[1
]}

Corso, A ^{[1
]}

Lazzarino, M ^{[1
]}

Bernasconi, C ^{[1
]}

机构：

[1] Univ Pavia, IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy

来源：

BLOOD | 2000年 / 96卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4627

引用

页码：210B / 210B

页数：1

共 50 条

[41] A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)
Vidal, Valerie
Hamri, Laila
Marceau-Renaut, Alice
De Fontbrune, Flore Sicre
Eclache, Virginie
Osman, Nevine
Papoular, Benjamin
Lusina, Daniel
Brechignac, Sabine
De Latour, Regis Peffault
Preudhomme, Claude
Gardin, Claude
Braun, Thorsten
BLOOD, 2018, 132
[42] MITOXANTRONE, ETOPOSIDE, AND INTERMEDIATE-DOSE CYTARABINE - AN EFFECTIVE AND TOLERABLE REGIMEN FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID-LEUKEMIA
AMADORI, S
ARCESE, W
ISACCHI, G
MELONI, G
PETTI, MC
MONARCA, B
TESTI, AM
MANDELLI, F
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) : 1210 - 1214
[43] Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia
Lee, JH
Choi, SJ
Lee, JH
Lee, YS
Seol, M
Ryu, SG
Jang, S
Park, CJ
Chi, HS
Lee, JS
Kim, WK
Lee, KH
LEUKEMIA RESEARCH, 2006, 30 (02) : 204 - 210
[44] Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma
Doorduijn, JK
Spruit, PH
Van der Holt, B
Van't Veer, MB
Budel, LM
Löwenberg, B
Sonneveld, P
HAEMATOLOGICA, 2000, 85 (08) : 814 - 819
[45] MITOXANTRONE AND HIGH-DOSE ETOPOSIDE FOR PATIENTS WITH RELAPSED OR REFRACTORY ACUTE-LEUKEMIA
OBRIEN, S
KANTARJIAN, H
ESTEY, E
KOLLER, C
BERAN, M
MCCREDIE, K
KEATING, M
CANCER, 1991, 68 (04) : 691 - 694
[46] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
Halpern, Anna B.
Buckley, Sarah A.
Othus, Megan
Huebner, Emily M.
Orlowski, Kaysey F.
Scott, Bart L.
Perdue, Andrea M.
Smith, Heather A.
Becker, Pamela S.
Hendrie, Paul C.
Cassone, Stephanie
Chen, Tara L.
Stirewalt, Derek L.
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2016, 128 (22)
[47] Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951
Wells, RJ
Adams, MT
Alonzo, TA
Arceci, RJ
Buckley, J
Buxton, AB
Dusenbery, K
Gamis, A
Masterson, M
Vik, T
Warkentin, P
Whitlock, JA
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2940 - 2947
[48] Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee, JH
Choi, SJ
Lee, JH
Lee, YS
Seol, M
Ryu, SG
Lee, JS
Kim, WK
Lee, KH
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 611S - 611S
[49] Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia
Abbi, Kamal K. S.
Rybka, Witold
Ehmann, W. Christopher
Claxton, David F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 41 - 46
[50] Clinical outcomes in patients with relapsed/refractory acute leukemia treated with FLAG-IDA regimen.
Basquiera, Ana L.
Prates, M. Virginia
Sturich, Ana Gabriela
Berretta, Adriana R.
Milone, Jorge
Garcia, Juan
BLOOD, 2006, 108 (11) : 220B - 220B

← 1 2 3 4 5 →